TippingPoint Biosciences Raises $4.5M Seed Round Led by SOSV to Develop Chromatin-Targeting Cancer Drug Platform
TippingPoint Biosciences, a San Francisco-based biotech startup developing next-generation therapeutics for cancer and other diseases driven by chromatin dysfunction, has raised $4.5 million in seed funding as it advances its platform for targeting previously “undruggable” epigenetic protein interfaces.
The financing was led by SOSV and LKS Fund, with participation from a syndicate of investors including Sazze Partners, Freeflow Ventures, StoryHouse Ventures, Sontag Innovation Fund, American Cancer Society BrightEdge, XEIA Ventures, and WeCAN. These backers bring a mix of venture capital, impact investing, and life sciences expertise focused on early-stage drug discovery and oncology innovation.
The company is developing a proprietary drug discovery platform designed to target disease-specific chromatin states—complex DNA packaging structures inside cells that play a key role in gene regulation and are often disrupted in cancer. Unlike traditional approaches that target individual epigenetic enzymes, TippingPoint’s technology aims to identify transient protein-protein interfaces that only appear in disease states, enabling more selective and potentially less toxic therapies.
TippingPoint Biosciences was founded in 2023 by CEO Dr. Laura Hsieh, a former postdoctoral researcher at the University of California, San Francisco (UCSF), working in the lab of chromatin biologist Dr. Geeta Narlikar. The company’s scientific foundation emerged from academic research focused on understanding how chromatin structure influences disease progression, particularly in aggressive pediatric cancers.
The startup is initially focusing its lead program on Diffuse Intrinsic Pontine Glioma (DIPG), a rare and highly aggressive pediatric brainstem cancer with very limited treatment options and extremely poor survival rates. By recreating disease-specific chromatin environments in controlled systems, the company aims to expose novel molecular targets that cannot be identified using conventional drug discovery methods.
TippingPoint’s approach is based on the idea that many cancer-driving interactions exist only under specific cellular conditions. By reconstructing these conditions in vitro, the platform allows researchers to identify and validate drug targets that are invisible in traditional biochemical assays. The company believes this strategy could unlock a new class of precision medicines for cancers and other diseases involving chromatin dysfunction.
The seed funding will be used to advance proof-of-concept studies, expand the company’s epigenetic interface discovery platform, and accelerate development of its lead therapeutic candidates toward preclinical validation. A key milestone will be testing candidate molecules in disease models of DIPG and other chromatin-driven cancers.
Investor participation in the round reflects growing interest in epigenetic and platform-based drug discovery approaches, particularly in oncology. Firms such as SOSV and LKS Fund have been active in backing early-stage biotech companies working at the intersection of synthetic biology, computational biology, and precision medicine.
With its new capital, TippingPoint Biosciences is positioning itself as a pioneer in a new frontier of drug discovery—one that seeks to move beyond conventional target-based approaches and instead exploit the dynamic structural states of chromatin to identify highly specific therapeutic opportunities in some of the most challenging diseases in oncology.
